BiotechTube
AnaMar Medical

AnaMar Medical

Lund, Sweden· Est.
anamar.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

AnaMar Medical is a privately held, clinical-stage biotech company pioneering a novel anti-fibrotic therapy. Its lead asset, AM1476, is a highly selective 5-HT2B receptor antagonist that is Phase II-ready, supported by positive Phase I safety data and preclinical proof-of-concept. The company is seeking partnerships to advance its program in systemic sclerosis and leverage its platform in broader fibrotic disorders, combining therapeutic development with biomarker and genetic analysis for targeted treatment.

FibrosisSystemic Sclerosis

Technology Platform

Platform for developing highly selective, peripherally-acting small molecule antagonists of the 5-HT2B serotonin receptor for the treatment of fibrotic diseases.

Opportunities

The significant unmet need in fibrotic diseases, particularly in orphan indications like systemic sclerosis, allows for premium pricing and expedited regulatory pathways.
Success in systemic sclerosis could serve as a proof-of-concept to expand into larger fibrotic markets such as IPF or liver fibrosis, leveraging the same platform.

Risk Factors

The primary risk is clinical failure of the single lead asset, AM1476, in upcoming trials.
The company is also dependent on securing a partnership to fund Phase II development, creating execution risk.
The competitive fibrosis landscape and the complexity of the disease biology present additional scientific and commercial challenges.

Competitive Landscape

The fibrosis therapeutic area is competitive with multiple mechanisms (e.g., TGF-beta, LOXL2, PPAR agonists) in development by both large pharma and biotech. AnaMar's differentiation lies in its highly selective, peripheral-acting 5-HT2B antagonism, a novel mechanism with potential for a favorable safety profile and dual action on skin and lung fibrosis in systemic sclerosis.

More companies in Small Molecule Drugs →More companies in Sweden →